| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |